Clinical Trial Update: Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the combination of carboplatin and cetuximab for Stage IIIB/IV non-small cell lung cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Cetuximab (cetuximab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED